Publikationen in Zusammenarbeit mit Forschern von Samsung Medical Center (7)

2021

  1. RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5258-5271

2020

  1. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

    Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535

2019

  1. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    Cancer, Vol. 125, Núm. 22, pp. 3974-3984

2018

  1. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial

    Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947

  2. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

    New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763

2015

  1. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 7, pp. 763-774

2014

  1. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

    International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16